Recommended Articles
Fundraising

European Healthtech and Deeptech Funding Surges, Led by Sava

By Angeled · October 25, 2026 · Fundraising
European Healthtech and Deeptech Funding Surges, Led by Sava
European Healthtech and Deeptech Funding Surges, Led by Sava

European startups recorded a strong run of healthtech and deeptech financing in October 2026, led by a London glucose-sensor company, a large health-data commitment, and a new fund for early-stage deeptech. A roundup of the week's activity highlights five transactions that together illustrate where European venture capital is concentrating: chronic-disease devices, hospital operations, cell analysis for immunotherapy, and the funds that back deep technology from its earliest stages.

Readers should note the nature of the source material. The five deals below are reported together in a single weekly roundup; individual company announcements vary in detail, and where a figure is described as a commitment rather than a closed round, this article says so.

Sava: €32.08 Million and a Distribution Partner for Glucose Sensing

The largest named deal is Sava Technologies, a London-based healthtech company developing a wearable biosensor platform that measures molecules just beneath the skin. Sava raised €32.08 million (about $36 million) in a Series B round to fund manufacturing scale-up and commercial readiness. The round was led by Ascensia, with participation from Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, and Pentland Ventures, among others. The round brings Sava's total funding to €60.6 million.

Alongside the financing, Sava appointed Ascensia, a subsidiary of PHC Holdings Corporation, as its commercialisation and distribution partner, initially in Europe. That pairing β€” capital plus distribution β€” is the deal's most important feature. Medical devices do not sell themselves; they require regulatory navigation, clinical relationships, reimbursement pathways, and a sales force that hospitals, pharmacies, and diabetes-care providers already trust. By partnering with an established diabetes-care company, Sava avoids building that entire apparatus from scratch.

Founded in 2019 by Imperial College London bioengineers Renato Circi and RafaΓ«l Michali, Sava spent five years in stealth before emerging in June 2024. Its platform starts with glucose monitoring but is designed to track additional biomarkers over time. The company says its microsensors are approximately 10 times shorter than traditional continuous glucose monitor filaments, minimising skin disruption β€” a claim about comfort and wearability that, if borne out in clinical use, could matter as much as accuracy for long-term adoption.

Circi's framing is blunt: "For decades, continuous monitoring has been held back by the same legacy technology. This is about to change." The next test is execution: scaling manufacturing, securing regulatory clearance in target markets, and converting a distribution partnership into real patient adoption.

Penelope Health: An €87 Million Commitment at Scale

Penelope Health secured a capital commitment of €87 million to scale operations, according to the roundup, which also reports that the firm reaches 200 million patients covered. The roundup does not provide the same level of detail for Penelope as for Sava β€” no lead investor, round label, or use-of-funds breakdown is given in the summary β€” so this article reports the commitment and the patient-coverage figure as reported, without adding detail that has not been verified.

Health Force and SpectaCell: AI Operations and Cell Analysis

Two smaller, earlier deals round out the healthtech picture. Health Force, based in Barcelona, closed a €4.2 million round to deploy AI agents aimed at optimising hospital management systems. Hospitals are among the most operationally complex organisations in any economy β€” scheduling, staffing, bed management, procurement, and billing all interact β€” and AI agents that can coordinate across those systems promise efficiency gains without requiring hospitals to replace their core software. The challenge, as with all hospital technology, is integration, data governance, and procurement cycles that move slowly even when the technology works.

SpectaCell, operating out of Ghent, launched with €6 million in funding to advance its cell analysis platform for immunotherapy research. Immunotherapy β€” treatments that harness the patient's own immune system against disease, notably cancer β€” depends on understanding cells in fine detail: which cells are present, what state they are in, and how they respond to treatment. Better cell analysis tools can accelerate research and, eventually, help match patients to therapies more precisely. SpectaCell's launch funding positions it at the research end of the healthtech spectrum, where timelines are long but scientific differentiation can be durable.

Monte Carlo Capital Fund II: €13 Million for Deeptech, AI, and Space

On the investor side, venture firm Monte Carlo Capital announced the successful closure of €13 million for its Fund II, targeting early-stage startups focused on deeptech, artificial intelligence, and space technology. A €13 million fund is small by venture standards, but small early-stage funds play a specific role: they can move quickly, take concentrated bets, and support founders in sectors where large funds may wait for more traction. For deeptech founders β€” who often need capital before revenue exists, to prove a technology rather than a market β€” that early, specialist capital can be decisive.

What It Means for Founders and Investors

Angeled.com connects founders with investors.

Sources: N24 weekly roundup, https://n24.com.tr/en/business/european-startup-funding-surges-across-healthtech-and-ai ; EU-Startups on Sava, https://www.eu-startups.com/2026/10/londons-sava-raises-e32-08-million-and-partners-with-ascensia-to-bring-its-glucose-microsensor-to-europe/

Read Next